Back to All NewsAbbVie Wins Bid to Block U.S. Imports of a Botox Rival
Posted By American Med Spa Association, Thursday, December 17, 2020
Share
AbbVie Inc. won a trade secrets case against a Botox rival, with an order that calls for U.S. imports of the Jeuveau wrinkle treatment to be halted for 21 months.
The U.S. International Trade Commission on Wednesday upheld a judge’s finding that Evolus Inc. and its partner Daewoong Pharmaceutical Co. manufactured the treatment with a secret process stolen from Abbvie’s South Korean partner, although it said a bacterial strain involved isn’t covered by trade secrets. The ruling reduces an initial 10-year ban proposed by the judge, which was based on his findings that the bacterial strain was a trade secret.
Read more at Bloomberg >>
The U.S. International Trade Commission on Wednesday upheld a judge’s finding that Evolus Inc. and its partner Daewoong Pharmaceutical Co. manufactured the treatment with a secret process stolen from Abbvie’s South Korean partner, although it said a bacterial strain involved isn’t covered by trade secrets. The ruling reduces an initial 10-year ban proposed by the judge, which was based on his findings that the bacterial strain was a trade secret.
Read more at Bloomberg >>
